▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion Pharmaceuticals by contacting: https://contactazmedical.astrazeneca.com.
Please refer to the Summary of Product Characteristics for further information.
healthcare professional
The efficacy and safety profile of STRENSIQ® was assessed in clinical trials with patients, of various ages, who had HPP2–6
* 10 patients completed a 6-month treatment period and entered the extension phase of this study.2
† Nine patients reached adolescence (13–17 years old) during the study.1
‡ After 1 month of treatment, one patient withdrew from the study for elective scoliosis surgery.6
§ Exploratory efficacy measures included motor function, muscle strength, patient reported functional disability and patient reported pain.7
† Nine patients reached adolescence (13–17 years old) during the study.1
‡ After 1 month of treatment, one patient withdrew from the study for elective scoliosis surgery.6
§ Exploratory efficacy measures included motor function, muscle strength, patient reported functional disability and patient reported pain.7
Adapted from Whyte MP, et al. J Bone Miner Res. 2018;33(5):868–874.10
- The Radiographic Global Impression of Change (RGI-C) scale is used to assess changes in the skeletal burden of paediatric patients with HPP, and quantifies change in mineralisation and bone structure over time10
- The 7-point scale ranges from -3 (severe deterioration) to +3 (complete or near-complete healing)10
BOT-2, Bruininks-Oseretsky Test of Motor Proficiency, 2nd Edition; HPP, hypophosphatasia; PLP, plasma/serum pyridoxal 5′-phosphate; PPi, inorganic pyrophosphate; RGI-C, Radiographic Global Impression of Change; RSS, Rickets Severity Scale; TEAE, treatment-emergent adverse event.
This medicinal product has been authorised under ‘exceptional circumstances’. This means that due to the rarity of the disease it has not been possible to obtain complete information on this medicinal product.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion Pharmaceuticals by the following link: https://contactazmedical.astrazeneca.com/
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion Pharmaceuticals by the following link: https://contactazmedical.astrazeneca.com/